MVC-COV1901, a vaccine against COVID-19, is being developed by Taiwan-based Medigen Vaccine Biologics Corp. in collaboration with the United States National Institutes of Health and Dynavax.Current status: The vaccine is in phase I trial in Taiwan.Mode of Action: MVC-COV1901 is a protein subunit vaccine containing Spike (S) protein with CpG 1018 and aluminum content as adjuvant. Upon administration, the vaccine triggers the production of antibodies, thus building up immunity.Next milestone:The phase I trial is expected to be completed by December 2021.